Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Fulcrum Therapeutics Inc (NASDAQ: FULC) closed the day trading at $12.08 down -3.36% from the previous closing price of $12.5. In other words, the price has decreased by -$3.36 from its previous closing price. On the day, 0.76 million shares were traded. FULC stock price reached its highest trading level at $12.66 during the session, while it also had its lowest trading level at $12.02.
Ratios:
For a better understanding of FULC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.70 and its Current Ratio is at 17.70. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
On July 29, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4 to $12.
Leerink Partners Upgraded its Market Perform to Outperform on May 23, 2025, while the target price for the stock was maintained at $12.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’25 when Oltmans Curtis Gale sold 3,452 shares for $12.92 per share. The transaction valued at 44,600 led to the insider holds 10,252 shares of the business.
CURTIS G OLTMANS bought 3,452 shares of FULC for $44,876 on Dec 15 ’25. On Dec 08 ’25, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the 10% Owner of the company, sold 4,175,139 shares for $13.98 each. As a result, the insider received 58,377,021 and left with 6,053,960 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FULC now has a Market Capitalization of 796921152 and an Enterprise Value of 460116736.
Stock Price History:
The Beta on a monthly basis for FULC is 3.18, which has changed by 2.101737 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, FULC has reached a high of $15.74, while it has fallen to a 52-week low of $2.32. The 50-Day Moving Average of the stock is 21.47%, while the 200-Day Moving Average is calculated to be 72.95%.
Shares Statistics:
Over the past 3-months, FULC traded about 1.26M shares per day on average, while over the past 10 days, FULC traded about 4385220 shares per day. A total of 65.97M shares are outstanding, with a floating share count of 58.52M. Insiders hold about 11.30% of the company’s shares, while institutions hold 67.44% stake in the company. Shares short for FULC as of 1764288000 were 3806493 with a Short Ratio of 3.03, compared to 1761868800 on 3525229. Therefore, it implies a Short% of Shares Outstanding of 3806493 and a Short% of Float of 10.15.
Earnings Estimates
Fulcrum Therapeutics Inc (FULC) is currently under the scrutiny of 10.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.21 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.13 and -$1.21 for the fiscal current year, implying an average EPS of -$1.17. EPS for the following year is -$1.2, with 10.0 analysts recommending between -$0.85 and -$1.52.
